Science in Action (SIA) is a boutique preclinical contract research organization (CRO) founded in 2010 by immunologist Raanan Margalit. SIA is GLP-accredited for toxicology studies in multiple areas. SIA has extensive experience in tailor-made preclinical research in rodent models and in-vitro models. We are committed to the highest standards of research along with optimal accessibility in meeting your specific scientific needs.
We provide full In-Vivo and In-Vitro R&D services. Our services cover a wide range of therapeutic areas, disease models and research techniques. SIA has extensive experience in the areas of Oncology, Inflammation and Autoimmunity, Neurology, Diabetes, Metabolic and Liver Disorders, Surgical Models, Muscle Dysfunction, and Cell Therapy.
Our clients are private entrepreneurs, small start-ups, medium-size bio-medical companies located in Israel and abroad, and researchers from Israeli Academic Institutions and Clinical Centers. SIA’s personnel has over 80 years of accumulated scientic experience. Development of novel state of the art customized preclinical models is a common practice at SIA. These include complex microsurgical procedures, tailored to the customers' specific development programs.
We’re always happy to share our knowledge, this is free - call us today (+972-52-3400426) for consultation on model selection or any other matter.
Our motivation is to help medical-oriented companies to thrive and bring new therapies to market, and improve people’s lives. It is SIA’s privilege and pride to offer the knowledge, experience and services to promote this goal. We provide preclinical services in vivo and in vitro, and maximal support to our clients in order to advance potential new therapies towards clinical stages.
SIA is GLP-accredited offering to perform customized safety/toxicology studies under OECD-GLP regulations. We specialize in toxicity testing of pharmaceuticals, cell therapy, medical devices and more. Please contact us to discuss possible experimental platforms for safety testing of your product.
SIA encourages the development of new drugs from preliminary idea phase.
SIA offers partnership and conducts preclinical R&D needed for concept evaluation and initial validation. To this end, SIA conducts research internally and in collaboration with other researchers.
To see the multidisciplinary project portfolio and read more, please go to Proof Of Concept R&D.
PROOF OF CONCEPT R&D
SIA's philanthropic research supports the Israeli Duchenne Parent Association.
This is an eort to develop a cure for Duchenne Muscular Dystrophy (DMD). DMD is the most common, fatal genetic disorder diagnosed in childhood. It aects approximately 1 in every 3,500 male infants born.